Ignace Vergote - Concepedia

Author

Ignace Vergote

Also Known As

Adriaan Vanderstichele, Alicia Vázquez, Andrew Lee, Anne M van Altena, Anne M. van Altena, Annemarie Schratter-Sehn, B. Winter-Roach, Brown, Robert, C.L. Chang, Celine Vachon

1.9K

Publications

88.5K

Citations

134

H-Index

207

Concepts

All Affiliations

KU Leuven Kliniken Essen-Mitte Charité - Universitätsmedizin Berlin European Institute of Oncology Universitair Ziekenhuis Leuven

About

Ignace Vergote is an author at KU Leuven specializing in medicine, oncology, and obstetrics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	76	320	30.6K
2	Health Sciences	32	54	4.3K
3	Public Health	18	23	1.4K
4	Engineering	9	9	497
5	Applied Physiology	1	1	41

Ignace Vergote

624

Publications

70.2K

Citations

117

H-Index

Page 1

	Year	Citations
Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer Ignace Vergote, Claes G. Tropé, Frédéric Amant, New England Journal of Medicine	2010	2.5K
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer Mansoor R. Mirza, Bradley J. Monk, Jørn Herrstedt, New England Journal of Medicine	2016	2.4K
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer Antonio González-Martı́n, Bhavana Pothuri, Ignace Vergote, New England Journal of Medicine	2019	2.1K
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer Isabelle Ray‐Coquard, Patricia Pautier, Sandro Pignata, New England Journal of Medicine	2019	1.9K
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer Jonathan A. Ledermann, Philipp Harter, Charlie Gourley, New England Journal of Medicine	2012	1.9K
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial Éric Pujade-Lauraine, Jonathan A. Ledermann, Frédèric Selle, The Lancet Oncology Brca1/2 MutationMedicineCancer ManagementGynecologyOlaparib Tablets	2017	1.8K
ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma Nicole Concin, Xavier Matías‐Guiu, Ignace Vergote, International Journal of Gynecological Cancer Endocrine-related CancerMedicineCancer ManagementGynecologyEsgo/estro/esp Guidelines	2020	1.8K
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial Robert L. Coleman, Amit M. Oza, Domenica Lorusso, The Lancet Rucaparib Maintenance TreatmentMedicineRecurrent Ovarian CarcinomaGynecologyCancer Treatment	2017	1.7K
Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial Éric Pujade-Lauraine, Felix Hilpert, B. Weber, Journal of Clinical Oncology	2014	1.6K
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial Jonathan A. Ledermann, Philipp Harter, Charlie Gourley, The Lancet Oncology Olaparib Maintenance TherapySerous Ovarian CancerMedicineCancer ManagementGynecology	2014	1.4K

Page 1